EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of purchasers of the securities of Alkermes plc (NASDAQ: ALKS) resulting from allegations that Alkermes may have issued materially misleading business information to the investing public.

On November 6, 2017, U.S. Senator Kamala Harris announced that she is opening an investigation into Alkermes’ sales practices for its opioid-addiction treatment Vivitrol. Senator Harris stated that Alkermes “aggressively marketed” its medication, convincing judges and prison officials to use it rather than more proven addiction-treatment products, and spent hundreds of thousands of dollars lobbying policymakers. On this news, shares of Alkermes fell sharply during intraday trading on November 7, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Alkermes investors. If you purchased shares of Alkermes, please visit the firm’s website at http://www.rosenlegal.com/cases-1233.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171107006530/en/